Autologous peripheral blood stem cell treatment

Harter C, Schulze B, Goldschmidt H, Benner A, Geiss HK, Hoppe-Tichy T et al. Piperachlin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or foUowing autologous peripheral blood stem cell transplantation a prospective randomized trial. Bone Marrow Transplant 2006 37 373-79. 

Most hematological adverse effects associated with trimethoprim have been reported with co-trimoxazole. These include macrocytic and megaloblastic anemia, aplastic anemia, neutropenia, hypersegmentation of leukocytes, thrombocytopenia, and pancytopenia (12,61-63,75-79). Sulfonamides alone have not been associated with folate deficiency, but in combination with trimethoprim they can deplete folate stores in patients with preexisting deficiency of folate or vitamin B12 (80). Treatment with co-trimoxazole can impair the function of mobilized autologous peripheral blood stem cells (81). 

Between September 1995 and November 2000, 70 patients were vaccinated after autologous peripheral blood stem cell transplantation (ASCT ) with one of two formulations of Theratope (Biomira, Edmonton, Alberta, Canada) coupled with Detox B SE (Detox B) (Corixa, Hamilton, MT). The difference between the two formulations was that the later one has an increased ratio of STn conjugated to KLH compared to the first formulation. The vaccination schedule for the two different formulations was previously published as well as medical treatment history of ASCT patients 18). 

---